These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17552440)

  • 1. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a low molecular weight heparin on coagulation parameters in healthy cats.
    Vargo CL; Taylor SM; Carr A; Jackson ML
    Can J Vet Res; 2009 Apr; 73(2):132-6. PubMed ID: 19436582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of viscoelastic coagulation testing to monitor low molecular weight heparin administration to healthy horses.
    Tennent-Brown BS; Epstein KL; Whelchel DD; Giguère S
    J Vet Emerg Crit Care (San Antonio); 2013; 23(3):291-9. PubMed ID: 23656212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
    Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose determination of fondaparinux in healthy cats.
    Fiakpui NN; Hogan DF; Whittem T; Green HW; Shipley EA; Sederquist KA
    Am J Vet Res; 2012 Apr; 73(4):556-61. PubMed ID: 22452504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal absorption of low molecular weight heparin in animals and human subjects.
    Nissan A; Ziv E; Kidron M; Bar-On H; Friedman G; Hyam E; Eldor A
    Haemostasis; 2000; 30(5):225-32. PubMed ID: 11251329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
    White H; Sosnowski K; Bird R; Jones M; Solano C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
    Feuring M; Wehling M; Schultz A
    Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
    Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
    Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
    Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
    Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats.
    Schönig JC; Mischke RH
    Am J Vet Res; 2016 Jul; 77(7):700-7. PubMed ID: 27347822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
    Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
    J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.